<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01508637</url>
  </required_header>
  <id_info>
    <org_study_id>39833-D</org_study_id>
    <secondary_id>P50ES015915</secondary_id>
    <nct_id>NCT01508637</nct_id>
  </id_info>
  <brief_title>Diesel Exhaust and Vascular Function</brief_title>
  <acronym>CVDTRAP4</acronym>
  <official_title>Effect of Diesel Exhaust Exposures on Vascular Function in Humans: The Role of Sympathetic Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Environmental Health Sciences (NIEHS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Environmental Protection Agency (EPA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, sham- and placebo-controlled randomized study of effects of freshly-generated
      diluted diesel exhaust inhalation on vascular function. To examine role of adrenergic system
      a trial of alpha-blocker terazosin is also used. Each participant completes four study
      sessions, separated by at least three weeks: 1) Diesel exhaust inhalation (DE, controlled at
      300 micrograms/cubic meter for two hours) and terazosin (2 mg prior to inhalation exposure);
      2) DE plus placebo (matched for terazosin); 3) filtered air plus terazosin; and 4) filter air
      plus placebo. The investigators assess outcomes of blood pressure, forearm brachial artery
      ultrasound, and plasma measures of endothelial activation. The investigators hypothesize that
      DE exposure will be associated with increased blood pressure, decreased brachial artery
      diameter, and increased circulating endothelins, and that these effects will be attenuated by
      terazosin administration.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>30-90 minutes after exposure initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brachial artery diameter</measure>
    <time_frame>Assessed 30 minutes prior to exposure and 30 minutes post-exposure</time_frame>
    <description>The investigators anticipate vasoconstriction (post-exposure vs. pre-exposure) as observed in this conduit artery in response to exposure to Diesel Exhaust, compared to Filtered Air sham exposure.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Cardiovascular Effects</condition>
  <arm_group>
    <arm_group_label>Diesel Exhaust + Terazosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Diesel Exhaust + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Filtered Air + terazosin</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Filtered air + placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diesel Exhaust</intervention_name>
    <description>Freshly generated diesel exhaust, diluted to 300 micrograms/cubic meter. Exposures are two hours in duration.</description>
    <arm_group_label>Diesel Exhaust + Terazosin</arm_group_label>
    <arm_group_label>Diesel Exhaust + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Filtered Air</intervention_name>
    <description>Sham exposure, identical to conditions of diesel exhaust exposure, but with only air filtered of particles and volatile organic compound gases</description>
    <arm_group_label>Filtered Air + terazosin</arm_group_label>
    <arm_group_label>Filtered air + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terazosin</intervention_name>
    <description>2 mg by mouth, 90 minutes prior to exposure initiation</description>
    <arm_group_label>Diesel Exhaust + Terazosin</arm_group_label>
    <arm_group_label>Filtered Air + terazosin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation</description>
    <arm_group_label>Diesel Exhaust + placebo</arm_group_label>
    <arm_group_label>Filtered air + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy without chronic illness

          -  Body Mass Index 18.5 - 26.0

          -  tolerates 2 mg terazosin dose without unacceptable symptoms

          -  able to return for four exposure sessions

        Exclusion Criteria:

          -  any chronic disease

          -  tobacco user

          -  asthma

          -  elevated cholesterol

          -  obesity

          -  hypertension

          -  diabetes

          -  any chronic cardiovascular or pulmonary disease

          -  pregnancy or unwillingness to use effective contraception, if female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel D Kaufman, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Jansen, M.S.</last_name>
    <phone>206-616-6525</phone>
    <email>cvd1trap@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2012</study_first_submitted>
  <study_first_submitted_qc>January 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2012</study_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Joel Daniel Kaufman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>air pollution</keyword>
  <keyword>vasoconstriction</keyword>
  <keyword>blood pressure</keyword>
  <keyword>diesel exhaust</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terazosin</mesh_term>
    <mesh_term>Prazosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

